Best Practices in Early-Stage NSCLC - Self Study Final Assessment

Credits:
1.0 AMA PRA Category 1 Credit(s) ™, 1.0 ANCC Contact Hours, 1.0 ACPE
Launch Date:
August 30, 2021
Expiration Date:
December 31, 2021

Primary Audience:

Physicians, Pharmacists, Nurses

Relevant Terms:

Early Stage NSCLC

Assess your knowledge and competency regarding the evolving treatment landscape for patients with early stage NSCLC, emerging adjuvant therapies in NSCLC, and improving coordination within the interprofessional cancer care team to improve patient outcomes.

Kashif Ali, MD

Medical Oncologist/Hematologist 
Maryland Oncology Hematology 
Silver Spring, MD 

Dr. Kashif Ali is a respected and renowned medical oncologist and hematologist who has been honored as a Washingtonian “Top Doc” in 2016, 2017, 2018, and 2019. 

Dr. Ali focuses on providing exceptional and compassionate care to his patients. His background in molecular biology and work experience at the nation’s top cancer centers has further enhanced Dr. Ali’s expertise. 

Dr. Ali’s office uses the latest cutting-edge medical technology and actively participates in clinical trials. He provides personalized targeted treatments specific to each patient and patient support services. 

Rasheda Persinger, NP-C

Medical Oncology Lead NP 
Sidney Kimmel Cancer Center,  
Sibley Memorial Hospital 
Washington, DC 

Rasheda Persinger is the lead medical oncology nurse practitioner at Johns Hopkins Medicine’s Sibley Memorial Hospital. She brings more than 15 years of oncology experience in academia and community-based practice. Her experience includes solid tumors, hematological malignancies, bone marrow transplant, and managing patients in clinical research trials. She currently practices within thoracic oncology.  

Persinger is knowledgeable about symptom management and values a holistic approach when caring for oncology patients. She is deeply passionate about providing oncology education to patients and caregivers to improve patient outcomes and minimize gaps in care. Persinger obtained her undergraduate degree at Syracuse University and her master’s degree from The Catholic University of America. 

1.
Discuss emerging data from ongoing studies of targeted therapies in the adjuvant setting for early-stage NSCLC
2.
Review recent clinical data from emerging studies of immunotherapy with checkpoint inhibitors in the neoadjuvant and adjuvant/consolidation setting to optimize survival for patients with early-stage NSCLC
3.
Assess the role of biomarkers in treatment selection for early-stage NSCLC
4.
Implement strategies to improve care coordination within the interprofessional cancer care team to improve patient outcomes in early-stage NSCLC

Best Practices in Early-Stage NSCLC 

Launch Date: August 30, 2021

Expire Date: December 31, 2021

Estimated Time to Complete: 60 minutes 

This educational activity is jointly provided by AXIS Medical Education and ACCC 

This educational activity is supported by educational grants from  

AstraZeneca Pharmaceuticals and Merck Sharp & Dohme Corp. 

Target audience:  The primary target audience for this activity comprises members of the interprofessional clinical cancer care team including, but not limited to, oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals who are involved in the care of patients with early stage NSCLC.  

Overview:   

According to the National Cancer Institute, about 80% of cancer patients in the US are treated by community oncologists. Community oncologists treat several types of cancers and see a large volume of patients. In 2019, the FDA approved 11 new therapeutic agents or expansions in indications for existing drugs used in oncology and hematology practice. With the evolving treatment landscape with several novel emerging therapies for patients with early stage non-small cell lung cancer (NSCLC), clinicians would highly benefit from discussions with knowledgeable experts and peers in order to gain a fuller understanding of optimal treatment selection and sequencing strategies, integration of new therapies into practice, and consensus-aligned management of treatment-related adverse events (AEs).  

 This activity will offer three text-based self-study chapters that cover the role of adjuvant targeted therapies, biomarker testing, and care coordination for patients diagnosed with early-stage NSCLC. Each chapter will offer a foundational review of the topic area with reinforcement questions, along with case presentations with learner challenges in a variety of interactive formats.   

Learning Objectives

At the end of this educational activity, participants should be able to:  

  • Discuss emerging data from ongoing studies of targeted therapies in the adjuvant setting for early-stage NSCLC ​ 

  • Review recent clinical data from emerging studies of immunotherapy with checkpoint inhibitors in the neoadjuvant and adjuvant/consolidation setting to optimize survival for patients with early-stage NSCLC 

  • Assess the role of biomarkers in treatment selection for early-stage NSCLC ​ 

  • Implement strategies to improve care coordination within the interprofessional cancer care team to improve patient outcomes in early-stage NSCLC 

Faculty

Kashif Ali, MD  
Medical Oncologist/Hematologist  
Maryland Oncology Hematology  
Silver Spring, MD  

Rasheda Persinger, NP-C  
Medical Oncology Lead NP  
Sidney Kimmel Cancer Center 
Sibley Memorial Hospital  
Washington, DC  

ACCREDITED CONTINUING EDUCATION 

Accreditation Statement 

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and ACCC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians 

AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Credit Designation for Pharmacists 

This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit JA4008106-9999-21-037-H01-P. 

Credit Designation for Nursing 

AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours. 

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. 

AXIS Contact Information  

For information about the accreditation of this program please contact AXIS at info@axismeded.org. 

Disclosure of Conflicts of Interest  

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.   

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.  

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: 

Name of Faculty/Author/Steering Committee 

Reported Financial Relationship 

Rasheda Persinger, NP-C  

 

Consultant: AstraZeneca and Bristol Myers Squibb. 

Speaker’s bureau: Guardant Health 

Kashif Ali, MD  

Speaker’s bureau: Bristol Myers Squibb and Sanofi Genzyme. 

 

The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  

Name of Planner/Manager/Reviewer 

Reported Financial Relationship 

Leigh Boehmer, PharmD, BCOP 

Consultant: Pfizer, Inc. 

Latha Shivakumar, PhD 

Nothing to disclose 

Ronald Viggiani, MD 

Nothing to disclose 

Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC 

Nothing to disclose 

Abimbola Farinde, PhD., PharmD 

Nothing to disclose 

Dee Morgillo, MEd., MT(ASCP), CHCP 

Nothing to disclose 

Disclaimer   

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Disclosure of Unlabeled Use  

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

System Requirements 

Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux  

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above. For video playback, install the latest version of Flash or Quicktime 

Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above  

Method of Participation and Request for Credit  

  • Attend/participate in the educational activity and review all course materials.  

  • Complete the CE Attestation/Evaluation form online. 

  • Upon successful completion of the online form, with a passing test score of 66.7% or higher, your statement of completion will be presented to you to print.